MUCIN 1 in Prostate Cancer
Article Sidebar
Main Article Content
ABSTRACT
Despite extensive research efforts in prostate cancer for the last several decades, the disease remains a leading cause of cancer death in men in the developed world. A typical feature of prostate cancer initiation and progression is the landscape of genetic alterations, which changes the expression patterns of numerous molecules in prostate epithelial cells, where the disease originates. These aberrantly expressed proteins are tumor-associated antigens. Their uniqueness in tumors offers an avenue not only in advancing our understanding of prostate cancer but also in the search for better diagnostic and therapeutic tools. Mucin 1 is one of the most well-characterized tumor-associated antigens. The protein is overexpressed and aberrantly glycosylated following prostate cancer development, and influences certain disease factors including disease initiation, metastasis, and resistance to therapy. Mucin 1 possesses value as a biomarker in predicting prostate cancer prognosis and has been studied as a therapeutic target. This chapter provides an overview of the impact of Mucin 1 on prostate cancer and its clinical values.
Downloads
Metrics
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of individual chapters belongs to the respective authors. The authors grant unrestricted publishing and distribution rights to the publisher. The electronic versions of the chapters are published under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Users are allowed to share and adapt the chapters for any non-commercial purposes as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source. The books in their entirety are subject to copyright by the publisher. The reproduction, modification, republication and display of the books in their entirety, in any form, by anyone, for commercial purposes are strictly prohibited without the written consent of the publisher.